<DOC>
	<DOCNO>NCT00577837</DOCNO>
	<brief_summary>A Multi-center , Active-controlled ( 5 mg daily risedronate ) , Double-blind , Randomized , Sequential Escalating Dose Study Assess Safety , Pharmacokinetics Efficacy 100 , 150 , 200 mg Oral Risedronate Administered Monthly Six Months Postmenopausal Women Low Bone Mineral Density .</brief_summary>
	<brief_title>Safety , Pharmacokinetics , Efficacy 100 , 150 , 200 mg Risedronate Administered Women With Low BMD</brief_title>
	<detailed_description />
	<mesh_term>Risedronate Sodium</mesh_term>
	<mesh_term>Etidronic Acid</mesh_term>
	<criteria>postmenopausal 5 year base medical history ; follicle stimulate hormone estradiol evaluate patient less 65 year age , undergone hysterectomy without bilateral oophorectomy , ensure patient postmenopausal use follow medication within 3 month start study drug use follow medication 1 month time within 6 month prior start study drug : oral parenteral glucocorticoid ( 5 mg prednisone equivalent per day ) anabolic steroid estrogen , raloxifene estrogenrelated drug , eg , tamoxifen , tibolone , ( except low dose vaginal cream , tablet insertable estrogen ring progestogen calcitonin vitamin D supplement ( great 800 IU per day ) calcitriol , calcidiol , alfacalcidol bisphosphonate fluoride ( 10 mg per day ) strontium bone active agent parathyroid hormone heparin , warfarin , similar anticoagulant</criteria>
	<gender>Female</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>April 2013</verification_date>
</DOC>